Boehringer Ingelheim forges $395m peptide deal with Zealand

By Dan Stanton contact

- Last updated on GMT

Related tags: Boehringer ingelheim, Pharmacology, Pre-clinical development

Boehringer Ingelheim forges $395m peptide deal with Zealand
Boehringer Ingelheim has entered a collaboration to develop a peptide candidate for cardio-metabolic diseases in a deal that could net partner Zealand Pharma up to €295m ($395m).

The two companies are currently involved in a joint deal to develop dual-acting glucagon/GLP-1 receptor agonists to treat Type 2 diabetes, but the two firms announced this week a second collaboration will focus on developing a peptide against an undisclosed cardio-metabolic target from Danish biotech Zealand’s portfolio.

The two firms will work together on bringing a peptide candidate into preclinical development, with Boehringer Ingelheim responsible for the conduct of preclinical and clinical development, plus commercialization, and liable to pay Zealand up to €295m for the first successful compound, with further payments and milestones for any additional peptides.

The deal “demonstrates [Zealand’s} strong partner relations with Boehringer Ingelheim, leveraging Zealand’s expertise in the design and development of therapeutic peptides to now cover an additional target in the cardio-metabolic disease area,”​ said Zealand CEO David Solomon.

Michel Pairet, Boehringer Ingelheim’s Senior Vice President Corporate Division Research and Development non-clinical, added: “Partnering is key to our business strategy and the relationship with Zealand is a long-term and important one,” ​and the deal “will further complement and strengthen our own discovery and development efforts in the area of cardio-metabolic diseases.”

Zealand has raised its revenue guidance for 2014 up from €13m to €18m on the back of this announcement.

The two firms first formed a venture in 2011, with Boehringer Ingelheim obtaing the rights to Zealand’s GLP-1 candidate ZP2929 for the treatment of Type 2 diabetes and obesity.

However, in January this year the two companies changed the development plan and Boehringer Ingelheim selecting a new lead compound designed for once-weekly dosing replacing ZP2929. The financial terms – Zealand to receive up to €376m – remained the same, while the rights of ZP2929 returned to Zealand.

Related topics: Bio Developments

Related news

Show more

Follow us

Products

View more

Webinars